Literature DB >> 22855283

Angiographic and platelet reactivity outcomes with prasugrel 60 mg pretreatment and clopidogrel 600 mg pretreatment in primary percutaneous coronary intervention.

Yiding Li1, Bee-Choo Tai, Winnie Sia, Qian-Hui Phua, Mark A Richards, Adrian Low, Koo-Hui Chan, Swee-Guan Teo, Tiong-Beng Sim, Chi-Hang Lee, Matthew T Roe, Tiong-Cheng Yeo, Huay-Cheem Tan, Mark Y Chan.   

Abstract

Pretreatment with 60 mg of prasugrel is more effective than 300 mg of clopidogrel in reducing thrombotic complications with primary percutaneous coronary intervention (PCI). We compared angiographic outcomes and platelet reactivity between treatment with 60 mg of prasugrel and 600 mg of clopidogrel administered before primary PCI. In this single centre non-randomized study, 65 consecutive Asian patients with ST-elevation myocardial infarction (STEMI) received 60 mg of prasugrel before primary PCI. The pre- and post-PCI corrected thrombolysis in myocardial infarction frame count (CTFC) and the 8-h post-treatment platelet vasodilator-stimulated phosphoprotein (VASP) index was compared with a matched historical Asian STEMI cohort (n = 65) receiving 600 mg of clopidogrel pretreatment. Comparing the prasugrel and clopidogrel groups, the mean age was 54.1 ± 10.2 versus 55.5 ± 11.8 years, P = 0.238, and the mean body mass index was 24.6 ± 2.0 versus 24.7 ± 2.8 kg m(-2), P = 0.393. The mean pre-PCI CTFC was 82.1 ± 30.2 versus 86.1 ± 27.6, P = 0.045, and the mean post-PCI CTFC was 21.1 ± 13.9 versus 20.1 ± 9.2, P = 0.309. Pre-PCI coronary thrombi were visualised in 6.3 versus 18.1 %, P = 0.038. The median VASP index was 22.2 ± 24.5 versus 70.5 ± 17.5 %, P < 0.001, and high on-treatment platelet reactivity (VASP index > 50 %) was observed in 13.8 versus 84.3 %, P = 0.001. Rescue intracoronary glycoprotein inhibitors were administered to 29.7 versus 51.0 %, P = 0.018, respectively. Treatment with 60 mg of prasugrel before primary PCI was associated with lower platelet reactivity, a modest trend towards better pre-PCI angiographic outcomes, less pre-PCI coronary thrombi and less rescue glycoprotein inhibitor use compared with 600 mg of clopidogrel. The very high frequency of high on-clopidogrel platelet reactivity with 600 mg of clopidogrel in this Asian STEMI cohort deserves further study.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22855283     DOI: 10.1007/s11239-012-0782-y

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  16 in total

1.  CYP2C19 and PON1 polymorphisms regulating clopidogrel bioactivation in Chinese, Malay and Indian subjects.

Authors:  Mark Y Chan; Karen Tan; Huay-Cheem Tan; Pei-Tee Huan; Bei Li; Qian-Hui Phua; Hong-Kai Lee; Chi-Hang Lee; Adrian Low; Richard C Becker; Wen-Chong Ong; Mark A Richards; Agus Salim; E-Shyong Tai; Evelyn Koay
Journal:  Pharmacogenomics       Date:  2012-04       Impact factor: 2.533

2.  Outcome comparison of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results from the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Myocardial Infarction) randomized study.

Authors:  Giuseppe Patti; György Bárczi; Dejan Orlic; Fabio Mangiacapra; Giuseppe Colonna; Vincenzo Pasceri; Emanuele Barbato; Béla Merkely; István Edes; Miodrag Ostojic; William Wijns; Germano Di Sciascio
Journal:  J Am Coll Cardiol       Date:  2011-10-04       Impact factor: 24.094

3.  The flow cytometric VASP assay can be used to determine the effectiveness of clopidogrel in patients treated with abciximab.

Authors:  J W van Werkum; C A K van der Stelt; T H Seesing; J M ten Berg; C M Hackeng
Journal:  J Thromb Haemost       Date:  2007-01-29       Impact factor: 5.824

4.  Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study.

Authors:  Marc S Sabatine; Christopher P Cannon; C Michael Gibson; Jose L López-Sendón; Gilles Montalescot; Pierre Theroux; Basil S Lewis; Sabina A Murphy; Carolyn H McCabe; Eugene Braunwald
Journal:  JAMA       Date:  2005-09-04       Impact factor: 56.272

5.  Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers: an open-label trial.

Authors:  David S Small; Christopher D Payne; Prajakti Kothare; Eunice Yuen; Fanni Natanegara; Mei Teng Loh; Joseph A Jakubowski; D Richard Lachno; Ying G Li; Kenneth J Winters; Nagy A Farid; Lan Ni; Daniel E Salazar; Molly Tomlin; Ronan Kelly
Journal:  Clin Ther       Date:  2010-02       Impact factor: 3.393

Review 6.  Proton pump inhibitors, genetic polymorphisms and response to clopidogrel therapy.

Authors:  H Fernando; A M Dart; K Peter; J A Shaw
Journal:  Thromb Haemost       Date:  2011-05-05       Impact factor: 5.249

7.  Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (prasugrel, LY640315), a novel P2Y12 receptor inhibitor.

Authors:  Michihiro Hasegawa; Atsuhiro Sugidachi; Taketoshi Ogawa; Takashi Isobe; Joseph A Jakubowski; Fumitoshi Asai
Journal:  Thromb Haemost       Date:  2005-09       Impact factor: 5.249

8.  High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes.

Authors:  Laurent Bonello; Michel Pansieri; Julien Mancini; Roland Bonello; Luc Maillard; Pierre Barnay; Philippe Rossi; Omar Ait-Mokhtar; Bernard Jouve; Frederic Collet; Jean Pascal Peyre; Olivier Wittenberg; Axel de Labriolle; Elise Camilleri; Edouard Cheneau; Elma Cabassome; Françoise Dignat-George; Laurence Camoin-Jau; Franck Paganelli
Journal:  J Am Coll Cardiol       Date:  2011-07-26       Impact factor: 24.094

9.  Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.

Authors:  Laurent Bonello; Udaya S Tantry; Rossella Marcucci; Ruediger Blindt; Dominick J Angiolillo; Richard Becker; Deepak L Bhatt; Marco Cattaneo; Jean Philippe Collet; Thomas Cuisset; Christian Gachet; Gilles Montalescot; Lisa K Jennings; Dean Kereiakes; Dirk Sibbing; Dietmar Trenk; Jochem W Van Werkum; Franck Paganelli; Matthew J Price; Ron Waksman; Paul A Gurbel
Journal:  J Am Coll Cardiol       Date:  2010-09-14       Impact factor: 24.094

10.  Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial.

Authors:  Stephen D Wiviott; Dietmar Trenk; Andrew L Frelinger; Michelle O'Donoghue; Franz-Josef Neumann; Alan D Michelson; Dominick J Angiolillo; Hanoch Hod; Gilles Montalescot; Debra L Miller; Joseph A Jakubowski; Richard Cairns; Sabina A Murphy; Carolyn H McCabe; Elliott M Antman; Eugene Braunwald
Journal:  Circulation       Date:  2007-12-03       Impact factor: 29.690

View more
  1 in total

Review 1.  The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day.

Authors:  Dominick J Angiolillo
Journal:  Drugs       Date:  2012-11-12       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.